Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor

被引:246
作者
Claudel, T
Leibowitz, MD
Fiévet, C
Tailleux, A
Wagner, B
Repa, JJ
Torpier, G
Lobaccaro, JM
Paterniti, JR
Mangelsdorf, DJ
Heyman, RA
Auwerx, J
机构
[1] Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France
[2] Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France
[3] Ligand Pharmaceut Inc, San Diego, CA 92121 USA
[4] X Ceptor Therapeut, San Diego, CA 92121 USA
[5] Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA
关键词
D O I
10.1073/pnas.041609298
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A common feature of many metabolic pathways is their control by retinoid X receptor (RXR) heterodimers. Dysregulation of such metabolic pathways can lead to the development of atherosclerosis, a disease influenced by both systemic and local factors. Here we analyzed the effects of activation of RXR and some of its heterodimers in apolipoprotein E -/- mice, a well established animal model of atherosclerosis. An RXR agonist drastically reduced the development of atherosclerosis. In addition, a ligand for the peroxisome proliferator-activated receptor (PPAR)gamma and a dual agonist of both PPAR alpha and PPAR gamma had moderate inhibitory effects. Both RXR and liver X receptor (LXR) agonists induced ATP-binding cassette protein 1 (ABC-1) expression and stimulated ABC-l-mediated cholesterol efflux from macrophages from wild-type, but not from LXR alpha and beta double -/-, mice. Hence, activation of ABC-1-mediated cholesterol efflux by the RXR/LXR heterodimer might contribute to the beneficial effects of rexinoids on atherosclerosis and warrant further evaluation of RXR/LXR agonists in prevention and treatment of atherosclerosis.
引用
收藏
页码:2610 / 2615
页数:6
相关论文
共 39 条
[1]  
CANTORNA MT, 1994, J IMMUNOL, V152, P1515
[2]  
Colville-Nash PR, 1998, J IMMUNOL, V161, P978
[3]  
Costet P, 2000, J BIOL CHEM, V275, P28240
[4]   Metabolic effects of rexinoids: Tissue-specific regulation of lipoprotein lipase activity [J].
Davies, PJA ;
Berry, SA ;
Shipley, GL ;
Eckel, RH ;
Hennuyer, N ;
Crombie, DL ;
Ogilvie, KM ;
Peinado-Onsurbe, J ;
Fievet, C ;
Leibowitz, MD ;
Heyman, RA ;
Auwerx, J .
MOLECULAR PHARMACOLOGY, 2001, 59 (02) :170-176
[5]   The PPAR alpha-leukotriene B-4 pathway to inflammation control [J].
Devchand, PR ;
Keller, H ;
Peters, JM ;
Vazquez, M ;
Gonzalez, FJ ;
Wahli, W .
NATURE, 1996, 384 (6604) :39-43
[6]   INHIBITION OF NITRIC-OXIDE SYNTHESIS IN VASCULAR SMOOTH-MUSCLE BY RETINOIDS [J].
HIROKAWA, K ;
OSHAUGHNESSY, KM ;
RAMRAKHA, P ;
WILKINS, MR .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (04) :1448-1454
[7]   PPAR-γ agonists inhibit production of monocyte inflammatory cytokines [J].
Jiang, CY ;
Ting, AT ;
Seed, B .
NATURE, 1998, 391 (6662) :82-86
[8]   NONSTEROID NUCLEAR RECEPTORS - WHAT ARE GENETIC-STUDIES TELLING US ABOUT THEIR ROLE IN REAL-LIFE [J].
KASTNER, P ;
MARK, M ;
CHAMBON, P .
CELL, 1995, 83 (06) :859-869
[9]   Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse [J].
Kozarsky, KF ;
Donahee, MH ;
Glick, JM ;
Krieger, M ;
Rader, DJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (03) :721-727
[10]   Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels [J].
Kozarsky, KF ;
Donahee, MH ;
Rigotti, A ;
Iqbal, SN ;
Edelman, ER ;
Krieger, M .
NATURE, 1997, 387 (6631) :414-417